Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial

John Nemunaitis, et al. SITC 2015, November 2015 – Abstract available on the SITC website Download the poster here Poster Presentation

Published 13 November 2015
Categorized as -others, 2015, Publication, TG4010

Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development

20151112 SillaJen_Pexavec_Joint

Published 12 November 2015
Categorized as 2015, Pexa-Vec, Press release

Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection

20151103 TG1050 FINAL VERSION US

Published 4 November 2015
Categorized as 2015, Press release, TG1050

Transgene Reports Third Quarter 2015 Financial Results

20151021 PR US Q3 2015 FINAL

Published 21 October 2015
Categorized as 2015, Press release

Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York

23092015 PR ladenburg conf_EN

Published 23 September 2015
Categorized as 2015, Press release

Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.

Ophelie Godon, et al. Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article Publication

Published 18 September 2015
Categorized as -others, 2015, Publication, TG1050

Transgene Reports Financial Results for First Six Months of 2015 (interim report)

20150910 – PR 2015 H1 results final

Published 10 September 2015
Categorized as 2015, Press release

TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.

Elisabeth Quoix, et al. 16th World Conference on Lung Cancer. September 2015, Denver, Colorado Download the poster here Poster Presentation

Published 10 September 2015
Categorized as -others, 2015, Publication, TG4010

Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

20150908 PR TG4010 IASLC revised – BIS

Published 8 September 2015
Categorized as 2015, Press release, TG4010

Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer

19 August 2015_PR_IASLC curtain raiser_ENG

Published 19 August 2015
Categorized as 2015, Press release, TG4010

Posts pagination

Newer posts Page 1 … Page 43 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu